B

Butterfly Network

Handheld ultrasound device for point-of-care imaging

Clinical Development Manager - Clinical Development and Validation

Full-Time
$185k/yr+ Bonus + Equity
Mid
Bachelor's
New York, NY, USA+1 moreMore locations: Burlington, MA, USA
HybridTwo or more days in the office per week; travel up to 50% required.
Biology & BiotechRegulatory & Quality (Life Sciences)
No H1B Sponsorship

About the job

Requirements
  • A minimum of 3 years of research and development experience or equivalent.
  • A minimum of 5 years of experience utilizing ultrasound medical imaging and medical technologies in diverse clinical environments, with a firm understanding of product attributes that lead to positive user and patient outcomes.
  • ARDMS certification is required.
  • At least 5 years of experience in diagnostic ultrasound with point-of-care ultrasound market expertise is required; current RDMS, RVT, and/or RDCS registration is required.
  • Excellent organization and time management skills.
  • Demonstrated leadership capabilities.
  • Ability to work with minimal supervision.
  • Ability to understand both the clinical and business needs of the customer and Butterfly Network.
  • Ability to translate customer needs into clear product requirements for research and development.
  • Ability to apply diagnostic ultrasound in non-traditional ways.
  • Ability and willingness to travel up to 50%.
  • Candidates must be authorized to work in the United States.
Responsibilities
  • Assist with customer engagements, focus groups, user groups, advisory boards, and other market-related activities to collect, define, and validate commercial needs and requirements.
  • Work with clinical specialists, software, the integration team, and systems engineering to validate design outputs.
  • Develop working knowledge of diagnostic and monitoring tools used by point-of-care physicians in their practice.
  • Identify and report clinical trends gathered through scientific congresses, customer seminars, and education events.
  • Define, document, and execute clinical validation tests, including maintaining traceability to requirements.
  • Create, maintain, and distribute plans and reports promptly to support product development timelines.
  • Participate in system life-cycle and software integration testing.
  • Participate in reviews and improvement of requirements, design documents, and overall processes.
  • Create and provide input to product requirements definitions, clinical evaluation reports, clinical validation plans, and clinical validation reports.
  • Carry out the requirements of Butterfly Network's quality procedures.
  • Provide clinical support and input cross-functionally to the design and development process as needed.
  • Provide product support to Commercial, Marketing, Clinical Application, and other cross-functional teams.
  • Perform tasks supporting the role and its responsibilities.
Desired Qualifications
  • Multilingual fluency in English, spoken and written.
  • Ability to work effectively in a team environment.

About the company

Butterfly Network makes medical imaging tools, focusing on point-of-care ultrasound (POCUS). Its main product is the Butterfly iQ, a handheld ultrasound device that uses a single probe to scan the whole body. The iQ connects to a software platform, storing images, supporting telehealth, and providing advanced imaging tools. The device is sold to doctors, nurses, and medical technicians in hospitals, clinics, and rural settings, with revenue from device sales, software subscriptions, and educational resources. What sets Butterfly Network apart is its single-probe, portable design that aims to simplify ultrasound workflows and make high-quality imaging more affordable and accessible, especially in underserved areas. The company’s goal is to improve diagnostic access and patient outcomes worldwide by delivering cost-effective, easy-to-use ultrasound technology that integrates hardware and software in one connected system.

Company Size

201-500

Company Stage

IPO

Headquarters

Burlington, Massachusetts

Founded

2011

Get referred to Butterfly Network

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 39% to $32.6 million, lifting full-year guidance to $123 million.
  • Brazil authorization opened Latin America's largest ultrasound market in 2026.
  • Home and Community Care starts October 1, 2026, adding a new recurring revenue channel.

What critics are saying

  • Butterfly reported $12.9 million Q2 2026 net loss despite 71.4% gross margin.
  • Law360 shows Rose v. Butterfly Network securities litigation active in New Jersey.
  • Insider selling spiked in 2026, including CEO Joseph DeVivo's August 10 sale.

What makes Butterfly Network unique

  • Butterfly's Ultrasound-on-Chip reached market through Mendaera Focalist on October 1, 2026.
  • Butterfly iQ3 remains the only single-probe whole-body handheld ultrasound platform.
  • Butterfly Embedded extends chip licensing beyond devices into robotics, wearables, and neurotechnology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health, dental & vision insurance

Equity

401k

PTO

Flexible hybrid work

Parental leave

Home office stipend

Rewards & recognition program

LinkedIn Learning

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 1st, 2026
Mendaera's Focalist™ system launches with Butterfly's Ultrasound-on-Chip™ technology

Mendaera has launched a version of its Focalist system compatible with Butterfly Network's Ultrasound-on-Chip technology. This marks the first Butterfly Embedded partner technology to reach the market. Mendaera's FDA-cleared Focalist system combines handheld robotics, real-time imaging, and intelligent guidance software for image-guided needle procedures, including vascular access, regional nerve blocks, and organ access. The collaboration brings together imaging and robotics technologies with the aim of advancing digitally native, AI-enabled intervention. Butterfly's software-defined architecture enables a path towards AI-enabled image interpretation and robotic action. Mendaera and Butterfly will both exhibit at the American College of Emergency Physicians Scientific Assembly on 5-7 October 2026 in Chicago, Illinois.

Yahoo Finance
Sep 23rd, 2026
Pfizer and Butterfly Network lead AI healthcare push with revenues up to $63.7B

Butterfly Network is commercialising AI-enhanced ultrasound devices designed to assist clinicians with real-time scan guidance. The company generates approximately $112 million in revenue from its handheld iQ devices and related software platforms, including Compass AI and ScanLab, with a market capitalisation of roughly $2.2 billion. In November 2025, Butterfly's subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology. The deal includes a $15 million upfront payment, $10 million in annual licence fees, and additional milestone-based payments. Pfizer, with $63.7 billion in recent revenue and a market value of $158.1 billion, is applying biomolecular AI foundation models to accelerate drug discovery and development across its Global Biopharmaceuticals Business segment. The company combines large-scale therapeutic operations with machine learning applications in molecule design, trial productivity, and manufacturing efficiency.

Yahoo Finance
Sep 15th, 2026
Butterfly Network CAO sells 13,804 shares worth $101K to cover tax obligations

Megan Carlson, Chief Accounting Officer and Senior Vice President of Finance at Butterfly Network, sold 13,804 shares of Class A common stock on 4 September 2026, valued at approximately $101,000. The transaction was a non-discretionary sell-to-cover sale to satisfy tax withholding requirements from vesting equity awards. Following the sale, Carlson retains around 412,000 shares directly. The medical device company's stock delivered a 381% total return over the 12 months ending on the transaction date. Butterfly Network develops portable ultrasound imaging devices, including the Butterfly iQ and iQ+, which connect to smartphones and tablets for point-of-care diagnostics. The company has a market capitalisation of $2.1 billion and generated $112.1 million in trailing twelve-month revenue.

Yahoo Finance
Sep 3rd, 2026
Sam Altman-backed Merge Labs selects Butterfly Network as exclusive ultrasound chip supplier for brain interfaces

Merge Labs, a brain-interface startup backed by OpenAI and Sam Altman, has selected Butterfly Network as its exclusive ultrasound-on-chip supplier under a multiyear agreement. The deal includes upfront payments, development milestones, purchase commitments, access fees, and potential royalties, though specific amounts were not disclosed. Butterfly's semiconductor-based ultrasound architecture makes the system programmable and easier to embed in new devices. The company retained rights to license its technology to other partners. Butterfly's second-quarter revenue increased 39% to $32.6 million, with gross margin expanding to 71.4%. Adjusted EBITDA loss narrowed 78% to $1.4 million. Management raised full-year revenue guidance to $119 million to $123 million. Thirty-three hedge funds held Butterfly Network in the second quarter, up from 26 in the first quarter.

Yahoo Finance
Aug 26th, 2026
Three AI small caps poised for growth as interest rate hikes plateau

Central banks signalling fewer interest rate hikes could support early-stage AI companies outside big tech. A new screener has identified 29 AI small-cap stocks positioned to benefit from the next wave of machine learning and automation. Butterfly Network, a medical imaging company, combines handheld ultrasound devices with AI-powered Compass software. The firm recently posted record quarterly revenue with strong gross margins. However, it remains unprofitable and trades at a high price-to-sales multiple, whilst experiencing significant insider selling. Pagaya Technologies operates an AI-driven loan decisioning platform serving banks, fintechs, and auto lenders. The platform assesses and prices consumer and small business credit in real time. The screener surfaced 26 additional companies with similar growth potential in AI-powered sectors.